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Abstract
Bacterial cell walls contain peptidoglycan, an essential polymer made by enzymes in the Mur pathway. These proteins are
specific to bacteria, which make them targets for drug discovery. MurC, MurD, MurE and MurF catalyze the synthesis of the
peptidoglycan precursor UDP-N-acetylmuramoyl-L-alanyl-c-D-glutamyl-meso-diaminopimelyl-D-alanyl-D-alanine by the
sequential addition of amino acids onto UDP-N-acetylmuramic acid (UDP-MurNAc). MurC-F enzymes have been extensively
studied by biochemistry and X-ray crystallography. In Gram-negative bacteria, ,30–60% of the bacterial cell wall is recycled
during each generation. Part of this recycling process involves the murein peptide ligase (Mpl), which attaches the
breakdown product, the tripeptide L-alanyl-c-D-glutamyl-meso-diaminopimelate, to UDP-MurNAc. We present the crystal
structure at 1.65 A˚ resolution of a full-length Mpl from the permafrost bacterium Psychrobacter arcticus 273-4 (PaMpl).
Although the Mpl structure has similarities to Mur enzymes, it has unique sequence and structure features that are likely
related to its role in cell wall recycling, a function that differentiates it from the MurC-F enzymes. We have analyzed the
sequence-structure relationships that are unique to Mpl proteins and compared them to MurC-F ligases. We have also
characterized the biochemical properties of this enzyme (optimal temperature, pH and magnesium binding profiles and
kinetic parameters). Although the structure does not contain any bound substrates, we have identified ,30 residues that
are likely to be important for recognition of the tripeptide and UDP-MurNAc substrates, as well as features that are unique
to Psychrobacter Mpl proteins. These results provide the basis for future mutational studies for more extensive function
characterization of the Mpl sequence-structure relationships.
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Introduction
Bacterial cell walls are characterized by the presence of
peptidoglycan (murein), a macromolecule built from sugar and
peptide building blocks, with the sugars in an alternating
arrangement of N-acetylglucosamine (GlcNAc) and N-acetylmura-
mic acid (MurNAc). This peptidoglycan barrier helps to maintain
turgidity of the cell and balance the internal osmotic pressure [1].
Disruption of proper bacterial cell wall formation is an effective
strategy for combating bacterial infections using common
antibiotics, such as penicillins [2].
De novo peptidoglycan synthesis is carried out by a series of
enzymes that have been extensively studied biochemically and
structurally [3–5]. Briefly, MurA and MurB are involved in the
first steps of peptidoglycan assembly with the formation of UDP-
GlcNAc-enolpyruvate and UDP-MurNAc, respectively. The Mur
ligases, MurC, MurD, MurE and MurF, are then involved in
sequential addition of L- and D- amino acids [L-Ala, D-Glu, meso-
diaminopimelate (meso-A2pm) and D-Ala-D-Ala, respectively]
to form UDP-MurNAc-L-Ala-c-D-Glu-meso-A2pm-D-Ala-D-Ala
(Figure 1)[6]. This polymer is further processed by several
membrane and periplasmic enzymes to ultimately create the
peptidoglycan. MurC-F enzymes share a common reaction
mechanism, similar three-dimensional structures, and several
invariant residues that classifies them in the Mur ligase family
[7–10].
Recycling of the bacterial cell wall is believed to account for ,30–
60% of peptidoglycan synthesis in Gram-negative bacteria [11].
During this process, the cell wall is catabolized using transglycosi-
dases, amidases, endopeptidases and carboxypeptidases [12]. The
Mpl protein is used to link the breakdown component, the tripeptide
L-Ala-c-D-Glu-meso-A2pm (and also tetra- and pentapeptides), to
UDP-MurNAc (Figure 1). Mpl was first identified by sequence
similarity with MurC (,20–25% identity) [6] and was also,
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therefore, assigned to the Mur ligase family. Mpl is functionally
similar to MurC, as both mechanisms involve ligation of an amino
acid or peptide to UDP-MurNAc; in MurC, a single amino acid (L-
Ala) is attached and in Mpl, a tri-, tetra- or pentapeptide.
Mpl from Escherichia coli (EcMpl, 48% identity to PaMpl) has
been functionally characterized [13]. The first 3D structural
information was obtained from a truncated Mpl protein (2 out of 3
domains: UDP-MurNAc and ATP binding domains) from Neisseria
meningitidis (NmMpl, Midwest Center for Structural Genomics,
http://www.mcsg.org, PDB accession code 3eag, 54% sequence
identity to PaMpl, unpublished results). In contrast, numerous
crystal structures of the full-length MurC-F proteins (,15–25%
identity to PaMpl) have been determined, including Escherichia coli
MurD (EcMurD), E. coli MurE (EcMurE) and Mycobacterium
tuberculosis MurE, and E. coli MurF (EcMurF) and Streptococcus
pneumoniae MurF [10,14,15]. The numerous crystal structures of
MurC from different bacteria include apo forms of MurC from E.
coli (EcMurC, PDB 2f00 [16], 25% seq id to PaMpl), Haemophilus
influenzae MurC (HiMurC, PDB 1gqq, 25% seq id to PaMpl),
Thermotoga maritima MurC (TmMurC, PDB 1j6u [17], 21% seq id
to PaMpl), and ligand-bound MurC structures of HiMurC (PDB
1p3d and 1p31 [18] and 1gqy).
In this study, we have determined the crystal structure of a full-
length apo-Mpl protein from the permafrost bacterium Psychrobacter
arcticus 273-4, PaMpl (UniProt accession code Q4FVQ2_PSYA2,
locus name Psyc_0032, 505 amino acids) at 1.65 A˚ resolution and
have also biochemically characterized this enzyme. We have
analyzed the sequence features that differentiate Mpl from MurC-
F as well as the common regions shared by different Mpl enzymes.
Several features appear to be unique to Mpl from Psychrobacter
species that may be of importance to permafrost bacteria.
Materials and Methods
Protein production and crystallization
Clones were generated using the Polymerase Incomplete Primer
Extension (PIPE) cloning method [19]. The gene encoding Mpl
(GenBank: YP_263340, gi|71064613; UniProt: Q4FVQ2) was
amplified by polymerase chain reaction (PCR) from P. arcticus 273-
4 genomic DNA using PfuTurbo DNA polymerase (Stratagene) and
I-PIPE (Insert) primers that included sequences for the predicted 5’
and 3’ ends. The expression vector, pSpeedET, which encodes an
amino-terminal tobacco etch virus (TEV) protease-cleavable
expression and purification tag (MGSDKIHHHHHHENLYFQ/
Figure 1. Bacterial cell wall peptidoglycan synthesis. Schematic pathway of cell wall peptidoglycan metabolism adapted from Mengin-
Lecreulx et al. [6]. Enzymes MurC, MurD and MurE are involved in de novo synthesis of the bacterial cell wall peptidoglycan. In Gram-negative bacteria,
it is estimated that ,30–60% of the peptidoglycan is recycled, and involves the enzyme Mpl.
doi:10.1371/journal.pone.0017624.g001
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G), was PCR amplified with V-PIPE (Vector) primers. V-PIPE
and I-PIPE PCR products were mixed to anneal the amplified
DNA fragments together. E. coli GeneHogs (Invitrogen) competent
cells were transformed with the I-PIPE/V-PIPE mixture and
dispensed on selective LB-agar plates. The cloning junctions were
confirmed by DNA sequencing.
Expression was performed in selenomethionine-containing
medium at 310 K. Selenomethionine was incorporated via
inhibition of methionine biosynthesis [20], which does not require
a methionine-auxotrophic strain. At the end of fermentation,
lysozyme was added to the culture to a final concentration of
250 mg/ml, and the cells were harvested and frozen. After one
freeze/thaw cycle, the cells were sonicated in lysis buffer [50 mM
HEPES, pH 8.0, 50 mM NaCl, 10 mM imidazole, 1 mM Tris(2-
carboxyethyl)phosphine-HCl (TCEP)] and the lysate was clarified
by centrifugation at 32,5006 g for 30 min. The soluble fraction
was passed over nickel-chelating resin (GE Healthcare) pre-
equilibrated with lysis buffer, the resin washed with wash buffer
[50 mM HEPES, pH 8.0, 300 mM NaCl, 40 mM imidazole,
10% (v/v) glycerol, 1 mM TCEP], and the protein eluted with
elution buffer [20 mM HEPES, pH 8.0, 300 mM imidazole, 10%
(v/v) glycerol, 1 mM TCEP]. The eluate was buffer exchanged
with TEV buffer [20 mM HEPES, pH 8.0, 200 mM NaCl,
40 mM imidazole, 1 mM TCEP] using a PD-10 column (GE
Healthcare), and incubated with 1 mg of TEV protease per 15 mg
of eluted protein. The protease-treated eluate was run over nickel-
chelating resin (GE Healthcare) pre-equilibrated with HEPES
crystallization buffer [20 mM HEPES, pH 8.0, 200 mM NaCl,
40 mM imidazole, 1 mM TCEP] and the resin was washed with
the same buffer. The flow-through and wash fractions were
combined and concentrated for crystallization trials to 12.8 mg/
ml by centrifugal ultrafiltration (Millipore). PaMpl was crystallized
using the nanodroplet vapor diffusion method [21] with standard
JCSG crystallization protocols [22]. Sitting drops composed of
200 nl protein mixed with 200 nl crystallization solution were
equilibrated against a 50 ml reservoir at 277 K for 26 days prior to
harvest. The crystallization reagent that produced the PaMpl
crystal for structure determination consisted of 0.2 M sodium
acetate, 30% PEG-4000, and 0.1 M Tris-HCl, pH 8.5. No
cryoprotectant was added to the crystal. Initial screening for
diffraction was carried out using the Stanford Automated
Mounting system (SAM) [23] at the Stanford Synchrotron
Radiation Lightsource (SSRL, SLAC National Accelerator
Laboratory, Menlo Park, CA). The diffraction data were indexed
in monoclinic space group C2. The oligomeric state of PaMpl in
solution was determined using a 1630 cm Superdex 200 column
(GE Healthcare) coupled with miniDAWN static light scattering
(SEC/SLS) and Optilab differential refractive index detectors
(Wyatt Technology). The mobile phase consisted of 20 mM Tris-
HCl pH 8.0, 150 mM sodium chloride, and 0.02% (w/v) sodium
azide. The molecular weight was calculated using ASTRA 5.1.5
software (Wyatt Technology).
X-ray data collection, structure solution, and refinement
MAD data were collected at the SSRL on beamline 9–2 at
wavelengths corresponding to the high-energy remote (l1),
inflection point (l2) and peak (l3) of a selenium MAD experiment
using the BLU-ICE [24] data collection environment. The data
sets were collected at 100 K using a MarMosaic 325 CCD
detector (Rayonix, USA). The MAD data were integrated and
reduced using MOSFLM [25] and scaled with the program
SCALA [26]. The heavy atom sub-structure was determined with
SHELXD [27]. Phasing was performed with autoSHARP [28],
SOLOMON [29] (implemented in autoSHARP) was used for
density modification and ARP/wARP [30] was used for automatic
model building to 1.65 A˚ resolution. Model completion and
crystallographic refinement were performed with the l1 dataset
using COOT [31] and REFMAC5 [32]. The refinement protocol
included experimental phase restraints in the form of Hendrick-
son–Lattman coefficients from autoSHARP and TLS refinement
with one TLS group per domain. Data and refinement statistics
are summarized in Table 1 [33].
Validation and deposition
The quality of the crystal structure was analyzed using the
JCSG Quality Control server (http://smb.slac.stanford.edu/jcsg/
QC). This server verifies: the stereochemical quality of the model
using AutoDepInputTool [34], MolProbity [35], and WHATIF
5.0 [36]; agreement between the atomic model and the data using
SFcheck 4.0 [37] and RESOLVE [38], the protein sequence using
CLUSTALW [39], atom occupancies using MOLEMAN2 [40],
consistency of NCS pairs, and evaluates difference in Rcryst/Rfree,
expected Rfree/Rcryst and maximum/minimum B-factors by
parsing the refinement log-file and PDB header. Protein
quaternary structure analysis was performed using the PISA
server [41]. The depiction of the protein sequence on the
secondary structure was adapted from an analysis using PDBsum
[42], and all other renditions of the protein structure were
prepared with PyMOL [43]. Atomic coordinates and experimen-
tal structure factors for Mpl from P. arcticus 273-4 to 1.65 A˚
resolution (code 3hn7) have been deposited in the Protein Data
Bank (www.wwpdb.org).
Preparation of nucleotide precursors and peptides
The nucleotide precursor UDP-MurNAc was chemically
synthesized [44] and UDP-MurNAc-peptides were prepared as
described previously [45]. Radiolabeled UDP-[14C]MurNAc was
prepared from UDP-[14C]GlcNAc (11.5 GBq/mmol, Amersham
Biosciences), PEP, NADPH and purified His6-tagged MurA and
MurB enzymes, as described previously [9]. The dipeptide L-Ala-
D-Glu was synthesized chemically according to Sachs and Brand
[46] and the tripeptide L-Ala-c-D-Glu-L-Lys was synthesized by a
modified procedure of Schmidt et al. [47]. The tetrapeptide L-Ala-
c-D-Glu-L-Lys-D-Ala was generated by treatment of pentapeptide
L-Ala-c-D-Glu-L-Lys-D-Ala-D-Ala (Bachem) with purified E. coli
PBP5, as described earlier [48]. The latter enzyme was over-
expressed as a soluble His6-tagged form from the pET-PBP5s
plasmid and purified on Ni2+-NTA agarose using standard
procedures. meso-A2pm-containing peptides were prepared from
the corresponding UDP-MurNAc-peptides as follows: first, mild
acid hydrolysis (10 min at 100uC in 0.1 M HCl) of UDP-
MurNAc-peptides generated MurNAc-peptides, which were
purified by HPLC as mixtures of the two anomers a and b [49];
then, MurNAc-peptides were hydrolyzed to MurNAc and peptides
by incubation with purified N-acetylmuramoyl-L-alanine amidase
(E. coli AmiD) [50]. The released peptides were subsequently
purified by HPLC on a 3 mm ODS-Hypersil column
(0.46625 cm). Elution was with 0.05% trifluoroacetic acid for
the meso-A2pm-containing tripeptide, or with a gradient of
acetonitrile (from 0 to 20% in 30 min) in the same buffer for
other peptides, at a flow rate of 0.5 ml/min. Peptides were
quantified by amino acid analysis with a Hitachi L8800 analyzer
(ScienceTec) after hydrolysis in 6 M HCl for 16 h at 95uC.
Protein production for biochemical characterization
The pSpeedET:Pampl plasmid was used for over-expression of
the His6-tagged PaMpl protein in E. coli cells. In order to avoid any
potential contamination with the EcMpl protein, the E. coli strain
Crystal Structure of PaMpl
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MLD2502, which has a deletion of the chromosomal mpl gene
(BW25113 Dmpl::CmR) [13], was used as the host strain for these
experiments. Cells were grown at 37uC in 1 l of 2YT medium
(BioRad) supplemented with chloramphenicol and kanamycin (25
and 50 mg/ml, respectively). Growth was monitored at 600 nm
and the expression of Mpl was induced with 0.02% (w/v)
arabinose when the optical density of the culture reached 0.7.
Overproduction of PaMpl was observed following induction of
cultures with arabinose, as judged by SDS-PAGE analysis of cell
extracts performed as previously described using 13% polyacryl-
amide gels [51]. However, amounts of this protein recovered in the
supernatant fraction following cell disruption and centrifugation
were lower than those recovered previously with the EcMpl
ortholog [13] (data not shown). Cells were harvested 3 h later and
washed with cold 20 mM potassium phosphate buffer, pH 7.4,
containing 0.5 mM MgCl2 and 0.01% 2-mercaptoethanol (buffer
A). The cell pellet was resuspended in 10 ml of buffer A containing
protease inhibitors (complete EDTA-free, Roche) and disrupted by
sonication. The suspension was then centrifuged at 200,0006 g
with a Beckman TL100 centrifuge and the His6-tagged Mpl
protein present in the soluble fraction (supernatant) was purified at
4uC on Ni2+-nitrilotriacetate (Ni2+-NTA) agarose (Qiagen).
Binding of Mpl protein to the polymer was followed by extensive
washing with 45 ml of buffer A containing 300 mM KCl and
10 mM imidazole, and elution was done in 15 ml using a
discontinuous gradient of imidazole, from 10 to 300 mM. The
His6-tagged Mpl was eluted with 100 mM imidazole. After dialysis
of the corresponding fraction against 200 volumes of buffer A, the
Mpl preparation was applied onto 0.25 ml of cobalt resin
(TALON, Clontech) for a further purification-concentration step
to eliminate a 30-kDa contaminating protein frequently co-
purified with His-tagged proteins, which likely is the SlyD protein
[52]. After washing with buffer A containing 10 mM imidazole,
the His6-tagged Mpl protein was eluted with 0.5 ml of buffer A
containing 200 mM imidazole. The final purified fraction was
dialyzed against 100 volumes of buffer A and stored at 220uC
after addition of glycerol (10% final concentration). The final
preparation of PaMpl was concentrated to 1.2 mg/ml and was at
least 95% pure as judged by SDS-PAGE analysis. Mpl migrated as
a protein of ,57 kDa, consistent with the calculated value
(57,187 Da, including the His-tag). The yield was relatively good
at ,2 mg/liter of culture, which is, nevertheless, ,50 fold lower
than that routinely obtained with EcMpl. Protein concentrations
were determined by the Bradford method, using bovine serum
albumin as a standard [53], or by quantitative amino acid analysis
after hydrolysis of a sample in 6.0 M HCl for 24 h at 105uC. To
Table 1. Summary of crystal parameters, data collection and refinement statistics for PDB 3hn7.
Space group C2
Unit cell parameters a = 105.45 A˚, b = 52.76 A˚, c = 89.99 A˚, b= 98.47u
Data collection l1 MAD-Se l2 MAD-Se l3 MAD-Se
Wavelength (A˚) 0.9116 0.9793 0.9792
Resolution range (A˚) 29.0–1.65 29.0–1.65 29.0–1.69
Number of observations 196,918 195,361 182,672
Number of unique reflections 59,026 58,985 55,004
Completeness (%) 100 (100)a 100 (100)a 100 (100)a
Mean I/s(I) 11.5 (2.2)a 9.9 (1.7)a 10.5 (1.8)a
Rsym on I (%) 0.076 (0.51)a 0.093 (0.58)a 0.085 (0.54)a
Highest resolution shell (A˚) 1.69–1.65 1.69–1.65 1.73–1.69
Model and refinement statistics
Resolution range (A˚) 29.0–1.65 Data set used in refinement l1 MAD-Se
No. of reflections (total) 59,024b Cutoff criteria |F|.0
No. of reflections (test) 2,985 Rcryst 0.154
Completeness (% total) 100 Rfree 0.187
Stereochemical parameters
Restraints (RMSD observed)
Bond angle (u) 1.59
Bond length (A˚) 0.018
Average protein isotropic B-value (A˚2) 19.6c
ESU based on Rfree (A˚) 0.087
No. of protein residues/atoms 480/3728
No. of water molecules 588 (with 10 modeled in alternate positions)
aHighest resolution shell.
ESU = Estimated overall coordinate error [33].
Rsym =S|Ii-,Ii.|/S|Ii|, where Ii is the scaled intensity of the i
th measurement and ,Ii. is the mean intensity for that reflection.
Rcryst =S||Fobs|-|Fcalc||/S|Fobs|, where Fcalc and Fobs are the calculated and observed structure factor amplitudes, respectively.
Rfree = as for Rcryst, but for 5.1% of the total reflections chosen at random and omitted from refinement.
bTypically, the number of unique reflections used in refinement is slightly less that the total number that were integrated and scaled. Reflections are excluded due to
negative intensities and rounding errors in the resolution limits and cell parameters.
cThis value represents the total B that includes TLS and residual B components.
doi:10.1371/journal.pone.0017624.t001
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compare the oligomeric form of PaMpl determined by SEC/SLS
(see Protein production and crystallization) to that of EcMpl,
100 ml of 1.3 mg of EcMpl was loaded onto a Superdex 200
column (10/300 GL, GE Healthcare). The mobile phase consisted
of 20 mM potassium phosphate buffer pH 7.4, 0.15 mM NaCl,
0.01% 2-mercaptoethanol. The velocity was 0.5 ml/min and
protein elution was detected at 280 nm.
Assay for tripeptide ligase activity
The standard assay mixture (40 ml) contained 100 mM Tris-HCl
buffer, pH 8.4, 5 mM ATP, 5 mM MgCl2, 0.25 mM L-Ala-c-D-
Glu-meso-A2pm, 0.4 mM UDP-[
14C]MurNAc (500 Bq), and puri-
fied PaMpl enzyme (70 ng of protein). Mixtures were incubated for
30 min and reactions were stopped by the addition of 10 ml of acetic
acid, followed by lyophilization. The residues were dissolved in
150 ml of 50 mM ammonium formate, pH 3.2, and 130 ml-aliquots
were injected onto a Nucleosil 100C18 5 mm column (0.46615 cm,
Alltech-France) using the same buffer at 0.6 ml/min as the mobile
phase. Detection was performed with a radioactive flow detector
(model LB506-C1, Berthold) using the Quicksafe Flow 2 scintillator
(Zinsser Analytic) at 0.6 ml/min. Quantitation was carried out with
the Radiostar software (Berthold).
For determination of the kinetic constants, the same assay was
used with various concentrations of one substrate and fixed
concentrations of the others. In all cases, the substrate consump-
tion was ,20%, the linearity being ensured within this time
interval even at the lowest substrate concentration. The data were
fitted to the equation v=VmaxS/(Km+S) using the MDFitt software
developed by M. Desmadril (IBBMC, Orsay, France).
Identical assay conditions were used when other peptides were
tested as substrates. The buffer and pH used for the separation of
the radiolabeled substrate and product slightly varied depending
on substrate used: ammonium formate at pH 3.9 for L-Ala-D-Glu,
ammonium formate at pH 4.2 for L-Ala-c-D-Glu-meso-A2pm-D-
Ala, L-Ala-c-D-Glu-meso-A2pm-D-Ala-D-Ala, L-Ala-c-D-Glu-L-
Lys and L-Ala-c-D-Glu-L-Lys-D-Ala, and 50 mM ammonium
acetate at pH 5.0 for L-Ala-c-D-Glu-L-Lys-D-Ala-D-Ala.
Results
Sequence analysis
Mpl and MurC-F enzymes have three domains that are
classified in Pfam families [54], PF01225 (Mur ligase catalytic
domain), PF08245 (Mur ligase middle domain) and PF02875 (Mur
ligase glutamate binding/C-terminal domain). Mpl was reported
to exhibit significant sequence similarity with MurC when first
isolated and identified [6]. A multiple sequence alignment
(calculated using CLUSTALW [55] and depicted using ESPRIPT
[56]) between PaMpl, NmMpl, EcMurC, HiMurC, TmMurC with
MurD-F (EcMurD, EcMurE and EcMurF), shows that significantly
more residues are, indeed, conserved between Mpl and MurC
(,21–25% overall pair-wise sequence-based identity) than be-
tween Mpl and MurD-F (,15–17% overall pair-wise sequence
identity) (Figure 2). The highest variation is found in the C-
terminal, peptide-binding domain. Functionally, Mpl and MurC
cannot substitute for each other under normal physiological
conditions. However, overexpression of the E. coli mpl gene on a
multi-copy plasmid was shown to complement an E. coli
thermosensitive murC mutant, which indicated that Mpl could
also accept L-alanine as a substrate [13]. The sequence motif (S/
T)AFFDKRSK (residues 184–192 in PaMpl numbering), which is
conserved in all 17 annotated Mpl enzymes in the August 2009
UniProt database, is not present in other Mur ligases (Figure 2,
black bar). In addition, in these 17 Mpl enzymes, several insertions
(residues 141–152, 161–171, 262–285 and 444–450, Figure 2,
yellow bars) are found only in Psychrobacter Mpl enzymes (n.b. only
residues corresponding to 161–171 are also found in the NmMpl).
Overall structure
The cloning, expression, purification and crystallization of
PaMpl was carried out using standard Joint Center for Structural
Genomics (JCSG; http://www.jcsg.org) protocols as detailed in
Materials and Methods. The crystal structure of PaMpl was
determined by Multi-wavelength Anomalous Diffraction (MAD)
phasing to a resolution of 1.65 A˚. Data collection, model and
refinement statistics are summarized in Table 1. PaMpl is present
as a monomer in the crystal asymmetric unit (Figure 3). The final
model includes Gly0 (a remnant from cleavage of the expression
and purification tag); residues 1–209, 216–265, and 285–504 of
the protein (the full-length protein contains 505 residues); and 588
water molecules. Residues 210–215, 266–284 and 505 are
disordered in the crystal structure and have not been modeled.
The Matthews’ coefficient [57] is ,2.2 A˚3/Da, with an estimated
solvent content of ,45%. The Ramachandran plot produced by
Molprobity [35] shows that 98.1% of the residues are in the
favored regions with none in disallowed regions.
PaMpl can be divided into 3 distinct domains: the N-terminal UDP-
MurNAc-binding domain (ND, residues 1–102), the middle ATP-
binding domain (MD, residues 103–357) and the C-terminal
tripeptide-binding domain (CD, residues 358–505). The ND resembles
a Rossmann-type fold with a five-stranded, parallel b-sheet (b1–b5)
flanked by five a-helices (H1–H5) and 310-helix H6. The MD is a ten-
stranded, curved, mainly parallel b-sheet (b6–b15) flanked by helices
on each side (a-helices H7-H8 and H10-H13, and 310-helix H9). The
CD is a six-stranded, mainly parallel b-sheet (b16–b21) flanked on one
side by a-helices H14-H16 and 310-helix H17, and on the other by
H18–H19. These 3 domains are linked contiguously to form a
triangular-shaped molecule with dimensions of ,56660647 A˚3.
Structure comparisons
A superimposition of PaMpl onto the partial structure of the
NmMpl (ND and MD, PDB id 3eag) shows that the corresponding
domains are quite similar with an r.m.s.d. of 2.2 A˚ over 311 Ca
residues and a structure-based sequence identity of 57% (Figure 4).
However, a few notable differences, for example, include PaMpl
residues 141–152 (loop and helix, green), 262–285 (orange), and
Figure 2. Sequence comparison of Mpl to MurC-F enzymes. Multiple sequence alignment (CLUSTALW [55]) of Mpl with MurC-F, rendered
using ESPRIPT [56]. The pairwise sequence identity between Mpl and MurC is ,21–25%, and is less between Mpl and MurD-F, ,15–17%. The PaMpl
segment of residues 184–192 (black bar), comprised of the sequence motif (S/T)AFFDKRSK, is not present in Mur ligases and may be functionally
important in Mpl. This motif packs against residues 90–92 (green bar), which are unique to and conserved in Mpl proteins (from analysis of 17
annotated Mpl enzymes in the UniProt database, August 2009, data not shown). Residues 7–13 constituting the GI(C/G)GTFM motif (blue bar) and
Asp31 (blue circle) are likely to interact with UDP. Tyr182 (blue circle) is unique to Mpl and may be involved in substrate recognition. Residues that are
likely to be important in ATP binding are: Asn205, His323 and Asn327 (adenine-binding, magenta circles); Asp373 (ribose-binding, orange circle); and
Gly113, Lys114, Thr115, Thr116, Arg358 and His376 (tri-phosphate binding, cyan and orange circles). Metal-binding residues are likely to be Thr115,
Glu178 and His210. The Psychrobacter Mpl enzymes have several insertions (residues 141–152, 161–171, 262–285 and 444–450, yellow bars), which
may be related to cell wall recycling in these bacteria that survive in permafrost conditions.
doi:10.1371/journal.pone.0017624.g002
Crystal Structure of PaMpl
PLoS ONE | www.plosone.org 6 March 2011 | Volume 6 | Issue 3 | e17624
Crystal Structure of PaMpl
PLoS ONE | www.plosone.org 7 March 2011 | Volume 6 | Issue 3 | e17624
444–450 (helix, cyan) that represent insertions into the core
structure that are not present in NmMpl, the 161–171 loop
(yellow), which adopts a different conformation compared to the
corresponding loop (153–162) in NmMpl, and a disordered region
in PaMpl (210–215) that is ordered (loop 199–208, red) in NmMpl.
As Mpl is most similar in sequence and function to MurC and since
MurC-F enzymes have been compared in detail elsewhere [7,8,58],
we have restricted our comparisons to MurC structures (EcMurC
with bound Mg2+, PDB id 2f00 and HiMurC with substrate analogs
UDP-MurNAc-L-Ala (UMA) and a nonhydrolyzable ATP analog
AMPPNP (ANP) bound, PDB id 1p3d). PaMpl and EcMurC can be
superposed with an r.m.s.d. of 2.2 A˚ over 283 Ca atoms (representing
the most structurally conserved regions, ND and MD, as there is
variation in the orientation of CD). Residues in EcMurC that
correspond to the 3 domains of PaMpl are 1–118, 119–325 and 326–
483, respectively. PaMpl is larger than EcMurC, with major insertions
in the MD (255 vs. 207 residues in the MD). In a domain pair-wise
comparison, the respective ND, MD and CD superpose with r.m.s.d.s
of 1.4 A˚ (26% structure-based sequence identity), 2.1 A˚ (33%
sequence identity) and 2.1 A˚ (20% sequence identity) over 99, 195
and 125 Ca residues respectively. Flexible, multiple structure
alignment of PaMpl with EcMurC (PDB 2f00), HiMurC (PDB
1p31), and TmMurC (PDB 1j6u) using POSA [59] shows that these
proteins share a common structural core (Figure 5) consisting of 355
Ca residues with an r.m.s.d. of 2.7 A˚. Moreover, conformational
flexibility is inherent in the overall architecture of Mur enzymes as
illustrated by comparing the substrate-bound and apo structures of
MurC and MurF (Figure 6, C and D, respectively). Superposition of
the apo PaMpl structure with the substrate-bound structures of
HiMurC (PDB 1p3d and 1gqy) results in r.m.s.d.’s of 4.2 A˚ over 411
Ca residues and 4.9 A˚ over 414 Ca residues, as a result of significant
domain movements. The largest conformational difference is in the
disposition of the CD in Mpl, which is rotated 30u relative to ND and
MD, when compared to its disposition in MurC (Figure 6, A and C,
respectively). Detailed inspection of the individual domains reveals
that the region with the least sequence conservation between Mpl and
MurC proteins is in the CD as discussed later.
Oligomerization
PaMpl is present as a monomer in the crystal asymmetric unit
and crystal packing analysis using PISA [41] did not identify any
potential higher order oligomers in the crystal lattice. Analytical
SEC suggested a tetramer in solution (Figure 7C, highest peak in
the continuous blue curve). However, static light scattering
measurements indicated a molecular weight of 120.5 kDa
(Figure 7C, discontinuous blue curve) with an oligomeric state of
2.09, indicating that a dimer is the prominent oligomeric form in
solution (n.b. in cases of discrepancy between SEC and light
Figure 3. Crystal structure of PaMpl. (A) Stereo ribbon diagram of PaMpl highlighting the 3 domains: N-terminal domain (ND), green; Middle
Domain (MD), cyan; and C-terminal Domain (CD), yellow. (B) Diagram showing the secondary structure elements of PaMpl colored by domain and
superimposed onto its primary sequence, adapted from PDBsum (http://www.ebi.ac.uk/pdbsum), where a-helices and 310-helices are sequentially
labeled (H1, H2, H3 etc), b-strands are labeled (b1, b2, b3, etc), b-hairpins are indicated by red loops, and b- and c-turns are indicated as b and c.
doi:10.1371/journal.pone.0017624.g003
Figure 4. Comparison of crystal structures of full-length PaMpl
and truncated NmMpl. The crystal structure of truncated NmMpl
(grey, ND and MD only, PDB id 3eag) is similar to PaMpl (blue) and can
be superimposed with an r.m.s.d. of 2.2 A˚ over 311 Ca atoms with a
sequence identity of 57%. The main differences are: NmMpl lacks the
PaMpl-specific sequence segments 141–152 (green), 262–285 (orange)
and 444–450 (cyan); NmMpl residues 152–163 are positioned differently
compared to the corresponding residues 161–171 in PaMpl (yellow);
and the segment corresponding to a loop (residues 199–208, red) in
NmMpl is disordered in PaMpl (residues 210–215, flanking residues 209
and 216 are in red).
doi:10.1371/journal.pone.0017624.g004
Figure 5. Comparison of PaMpl and MurC structures. Superim-
position of PaMpl (blue) with EcMurC (PDB 2f00, pale green), HiMurC
(PDB 1p31, orange), and TmMurC (PDB 1j6u, grey) reveals a common
structural core of 355 Ca residues with an r.m.s.d. of 2.7 A˚.
doi:10.1371/journal.pone.0017624.g005
Crystal Structure of PaMpl
PLoS ONE | www.plosone.org 8 March 2011 | Volume 6 | Issue 3 | e17624
scattering, the light scattering results are more likely to represent
the dominant solution state). SEC also indicated that EcMpl is
dimeric in solution. In contrast, EcMurD (PDB 1uag), EcMurE
(PDB 1e8c) and EcMurF (PDB 1gg4), have been reported to be
monomers in the crystal and in solution. Interestingly, EcMurC
(PDB 2f00) is also a dimer in the crystal structure but, in solution,
displays a dynamic equilibrium between monomeric and dimeric
forms. Both forms were shown to be active [16,60]. The PFYG
Figure 6. Surface representation of different domain dispositions in Mur family structures. Crystal structures of: (A) apo-PaMpl, (B)
EcMurC with bound Mg2+, (C) HiMurC bound to substrates UDP-MurNAc-L-Ala (UMA) and AMPPNP (ANP), and metal; and (D) apo-EcMurF (on slightly
smaller scale compared to A–C as more extended conformation). For all proteins, ND is in green, MD is in cyan and CD is in yellow. These examples
illustrate the conformational variability of these Mur enzymes. All molecules are in the same orientation based on their superimposition on the PaMpl
MD. The CD of the apo-PaMpl is rotated 30u with respect to ND and MD compared to the MurC structure. The PaMpl domains may open up during
substrate binding and close during catalysis.
doi:10.1371/journal.pone.0017624.g006
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Figure 7. Oligomerization states of EcMurC and PaMpl. (A) The dimer observed in the crystal structure of EcMurC (PDB 2f00) with the domains
from each monomer labelled ND, MD, CD, and ND’, MD’, CD’; respectively, and the residues involved in dimer interactions highlighted as sticks. (B) A
detailed view of the residues involved in intermolecular contacts: F223 and Y224 from the MD of one protomer interact with M16’, V19’, V81’, I106’
and M111’ from ND’ of the other protomer. E306 and E307 from one protomer interact with R17’ and R18’ from the other protomer. (C) Profile of the
SEC/SLS experiment displaying the refractive index signal (SEC, continuous trace) against elution time (minutes) for PaMpl (blue) compared with a
molecular weight standard (red, BioRad gel filtration standard with 158, 44 and 17 kDa peaks representing bovine c-globulin, chicken ovalbumin and
horse myoglobin, respectively). The discontinuous trace represents the molar mass (g/mol) calculated by SLS. For PaMpl, the SEC profile suggested a
tetrameric form in comparison to the standard, but the more accurate molar mass estimated from SLS averaged across the majority of the peak was
120.5 kDa (as calculated by the ASTRA software (Wyatt Technology), with an oligomer number of 2.09, indicating a dimer as the dominant species in
solution.
doi:10.1371/journal.pone.0017624.g007
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(residues 222–225) motif in EcMurC (corresponding to PSTG,
residues 232–235, in PaMpl), which is conserved in ,50% of
MurC proteins, is involved in dimerization. Phe223 and Tyr224
(in the H7-b11 loop) from MD of one EcMurC monomer interact
with Met16 and Val19 (not found in Mpl) and Val81, Ile106 and
Met111 (corresponding positions in Mpl are Leu64, Thr89 and
Phe94) in a hydrophobic pocket in the ND of its dimer partner
(Figure 7, A and B). Also, Arg17 and Arg18 of EcMurC, which
form salt bridges with Glu306 and Glu307 respectively (Figure 7,
A and B), are not found in PaMpl. Thus, residues involved in
dimerization in PaMpl (and Mpl proteins in general) differ,
suggesting that the mode of dimerization may also be different.
ND:UDP-MurNAc binding region and MD:ATP and
magnesium binding region
Residues in the ND and MD that are important for interaction
with UDP-MurNAc, ATP and metal have been described for Mur
enzymes, and most of these residues are conserved in Mpl
(Figure 2). Analysis of protein-ligand interactions observed in the
HiMurC/UMA/ANP complex structure using LigPlot [61] shows
that many of the important residues are also structurally conserved
in PaMpl (Figure 8).
The glycine-rich loop GI(C/G)GTFM conserved across all Mpl
enzymes (Figure 2, blue bar, residues 7–13 in PaMpl) is also
present in MurC and other oxidoreductases [62], where it
interacts with UDP. However, the Phe at position 12 in PaMpl
is considerably larger than the corresponding glycine in MurC
enzymes. Although, the identity of the three residues that interact
with the uracil ring of UDP (HiMurC Ile50, Ile87 and His70;
EcMurC Leu51, Ile88 and His71 [16]) is not conserved in Mpl
(Ala32, Met71 and Tyr53 in PaMpl), the nature of the interactions
is conserved (main chain, hydrophobic and side-chain hydrogen
bond interactions with these 3 residues, respectively, Figure 8), as
the PaMpl does also bind to UDP as demonstrated by biochemical
characterization. Asp31 in PaMpl is conserved in almost all Mur
enzymes and is important for interactions with the diphosphate of
UDP (Figure 2, blue circle). Conserved residues in Mpl proteins
that are also in the vicinity of the UDP-MurNAc-binding pocket,
but are not structurally equivalent to those observed to interact
with ligands in the HiMurC structure (Figure 8), are Tyr35, Asn69,
Arg73 and Gly74, which could also be involved in recognition and
binding of UDP-MurNAc in Mpl (Figure 9). In addition, the Mpl-
specific region, which is conserved in the ND, comprises of SGP
(residues 90–92 in PaMpl) that packs against another conserved
loop (S/T)AFFDKRSK (residues 184–192, Figure 2, green and
black bars). These interactions could play a role in the different
positioning of ND and MD (so as to interact with both the UDP
and MurNAc moieties) compared to that in Mur enzymes
(Figure 9). Tyr182, which is unique to Mpl (Figure 2, blue circle
and Figure 9) and located just prior to the start of this loop, could
also be involved in substrate recognition. Thus, the various Mpl
residues described above are potentially involved in UDP-
MurNAc interactions and provide a guide for site-directed
mutagenesis to test their functional roles.
As for all other Mur enzymes, it is assumed that the ligation of
peptide to UDP-MurNAc should also be ATP-driven in Mpl and
that phosphorylation of the C-terminal carboxylate forms an acyl
phosphate intermediate, followed by the nucleophilic attack of
amino group of the amino acid or peptide substrate. Thus, in
PaMpl, the corresponding adenine binding residues would be
Asn205, His323 and Asn327 (Figure 2, magenta circles), the ribose
binding residue would be Asp373 (Figure 2, orange circle), and
residues that stabilize the tri-phosphate would be the GKTT motif
(P-loop found in kinases and ATPases, residues 113–116; Lys 114
corresponding to Lys129 in HiMurC and Lys130 in EcMurC)
(Figure 2, cyan circles), and Arg358 and His376 (Figure 2, orange
circles) [10]. These residues are all structurally conserved when
compared to the HiMurC ligand complex (Figure 8). Like MurC,
PaMpl activity (see Optimal conditions for enzyme activity)
is dependent on magnesium (in other structures of Mur ligases, two
Mg ions (Mg1, Mg2) per molecule are found), although no Mg2+ is
observed in our structure. Mg1 would interact with the b- and c-
phosphates of ATP and Mg2 would interact with the c-phosphate
based on available MurC structures. In EcMurC (PDB 2f00), only
Mg2 was observed due to the absence of ATP, whereas both
metals were observed in the complex structure of HiMurC (PDB
1p3d). Thus, the binding site of Mg1 in PaMpl is likely to be
comprised of Thr115 and Glu178 (corresponding to Thr130 and
Glu173 in HiMurC) with the remainder of the coordination sphere
completed by two water molecules and two oxygen atoms from the
phosphate groups of the ATP. The second metal binding site in
EcMurC and HiMurC is around His199 and His198, respectively,
with waters making up the remainder of the coordination sphere.
The corresponding residue in PaMpl is His210, but this region
(residues 210–215) is disordered in our structure, probably due to
the absence of metal ions. A loop (residues 404–414) from CD in
PaMpl is folded into part of the ATP and UDP-MurNAc binding
site (Figure 9). A significant conformational change is likely to
occur in this region upon binding substrates and cofactors and
involves ordering and closing of the His210 region towards Mg2
and opening of the CD. In the truncated NmMpl, which lacks CD,
the region corresponding to missing residues 210–215 in PaMpl is
ordered even in the absence of bound metal. Conserved residues
in Mpl proteins that are in the vicinity of the ATP-binding pocket,
but are not equivalent to those observed to interact with ANP in
HiMurC (Figure 8), are Tyr182, Gln223 and Phe224 (which is a
phenylalanine or tyrosine in MurC) (Figure 9). Phe224 corre-
sponds to a lysine in MurD (Lys198 in EcMurD), MurE and MurF
that is post-translationally carbamoylated. Several experiments
have demonstrated that this carbamoylated lysine is essential [63]
as it aids in the stability of Mg2 binding. In MurC, absence of this
lysine is compensated by presence of a glutamate that is also
conserved in Mpl enzymes (PaMpl Glu181) (Figure 9).
CD: tripeptide binding region
The CD of Mpl is functionally unique from MurC-F proteins
since it primarily attaches a tripeptide to UDP-MurNAc (n.b. it
can also attach a tetra or pentapeptide, but less efficiently). MurC
residues believed to be involved in binding to the incoming amino
acid are His376, Arg377, Arg380, Tyr346 and His348 as observed
in the HiMurC-product complex (PDB 1p3d) (Figure 8, n.b.
Tyr346 is not seen in this representation). In the case of MurE, it is
believed that Arg416 should be the main determinant for peptide
selectivity [64]. The various Mur enzymes, as well as Mpl, have
most variation in this CD domain (Figure 2), which reflects that
they are all likely to have different interactions with the incoming
Figure 8. PaMpl residues potentially involved in interactions with ATP and UDP-MurNAc. Schematic representation rendered using
LigPlot [61] of the interactions observed between HiMurC and ligands UDP-MurNAc-L-Ala (UMA) and AMPPNP (ANP) in the crystal structure (PDB id
1p3d). The majority of these residues in HiMurC (red labels) ND and MD are structurally conserved in PaMpl (blue labels), suggesting that Mpl and
MurC have similar interactions with ATP and UDP-MurNAc.
doi:10.1371/journal.pone.0017624.g008
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peptide substrate, but this aspect of Mur function remains the least
characterized. Conserved, solvent-exposed, Mpl-specific residues
in the CD are likely to be instrumental in defining substrate
specificity and include Arg357, Arg358, Phe374, Ala375, His376,
His377, Glu402, Pro403, Arg404, Ser405, Asn406, Thr407,
Ser483, Asn484 and Gly485, which may be important in binding
tri, tetra, and pentapeptide substrates (Figure 9). Based on their
location in the PaMpl structure, it seems likely that, if these
residues were to interact with peptide, the CD should undergo a
conformational change with respect to the ND and MD.
Figure 9. Additional Mpl-specific residues in ND, MD and CD that may be involved in substrate interactions. Model of PaMpl bound to
ANP, UMA and metal based on the superimposition of the ND and MD of PaMpl onto the corresponding domains from HiMurC (ND and MD are the
most conserved domains between the proteins) bound to ANP and UMA (PDB id 1p3d). After superimposition, the ligand coordinates were
transferred from HiMurC to generate the model of PaMpl bound to ligands. Numerous residues in the binding pocket are unique and conserved in
Mpl proteins and could be involved in additional interactions with substrates. These include ND Tyr35, Asn69, Arg73 and Gly74 (not shown). Ser90,
Gly91 and Pro92 pack against Mpl-specific loop consisting of Ser184 (Thr or Cys in different Mpl proteins), Ala185, Phe186, Phe187, Asp188 and
Lys189. Tyr182, which is directly upstream of this loop, could also be involved in the recognition. Mpl-specific residues in CD are likely to play a crucial
role in substrate specificity and include Arg357, Arg358, Phe374, Ala375, His376, His377, Glu402, Pro403, Arg404, Ser405 (in dual conformation),
Asn406, Thr407, Ser483 (in dual conformation), Asn484 and Gly485.
doi:10.1371/journal.pone.0017624.g009
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Kinetic parameters and substrate specificity of PaMpl
The expression and purification of PaMpl for biochemical
characterization was carried out as outlined in Materials and
Methods. The kinetic parameters of the PaMpl enzyme towards
its three substrates were determined (Table 2). These values
(kcat = 260620 min
21; Km = 1.0060.13 mM, 0.1160.05 mM and
0.3660.08 mM for UDP-MurNAc, ATP and L-Ala-c-D-Glu-
meso-A2pm, respectively) were generally similar to those previously
determined with the E. coli ortholog (kcat = 290 min
21;
Km = 0.2 mM and 0.1 mM for ATP and L-Ala-c-D-Glu-meso-
A2pm, respectively). The Km value obtained for UDP-MurNAc,
however, was significantly higher (Km EcMpl = 0.25 mM).
The substrate specificity of PaMpl was also investigated. As
shown in Table 3, tetrapeptide L-Ala-c-D-Glu-meso-A2pm-D-Ala
and pentapeptide L-Ala-c-D-Glu-meso-A2pm-D-Ala-D-Ala were
also accepted as substrates, but less efficiently. As the Michaelis-
Menten plots were linear up to 0.25 mM, it was only possible to
determine enzyme velocities at this concentration (k values for
these substrates were 5.960.6 min21 and 5.360.6 min21, respec-
tively). PaMpl activity was comparatively much lower with smaller
substrates L-Ala and L-Ala-D-Glu (k= 0.760.1 min21 and
1.460.2 min21, respectively) and substitution of meso-A2pm by
L-Lys in the tripeptide dramatically decreased enzyme activity
(k= 0.2560.05 min21 and 260620 min21 for L-Lys- and meso-
A2pm-containing tripeptides, respectively). A clear preference for
A2pm at the third position of the peptide had already been
observed with EcMpl, although to a lesser extent (kcat values of the
E. coli enzyme for these two tripeptides were 16 min21 and
290 min21, respectively) [13].
Optimal conditions for enzyme activity
Assessment of activity as a function of pH showed an optimal
pH value of 8.4 (Figure 10). Like EcMpl and all other Mur ligases
[13,65], PaMpl requires a divalent cation for activity. The optimal
concentration determined for Mg2+ was 5 mM (Figure 10). As P.
arcticus is a psychrophilic Siberian permafrost bacterium, a
comparative study of PaMpl and EcMpl activities as a function
of temperature was performed (Figure 10). At a low temperature
,15uC, the activity of PaMpl was almost twice that of EcMpl. The
optimal temperatures for these two enzymes were 30uC and 37uC,
respectively. The PaMpl activity was almost completely abolished
at 42uC, although EcMpl still retained 95% of its optimal activity
at this temperature.
Discussion
The high-resolution crystal structure of the full-length PaMpl
provides insights into the structure and relative orientations of the
three domains in this cell wall recycling enzyme. Analysis of
residues likely involved in binding UDP-MurNAc, ATP, metals
and tri, tetra and pentapeptide substrates combined with enzyme
kinetics and activity characterization, provide a basis for further
experimentation to explore the structure and function of Mpl
proteins. As a recycling enzyme, the role of Mpl is to attach the
tripeptide L-Ala-c-D-Glu-meso-A2pm to UDP-MurNAc. Structure
analyses indicate that the orientation of the CD domain of PaMpl
relative to the other domains is flexible and changes on substrate
binding. The pre-catalytic form of Mpl must open up to allow
UDP-MurNAc to bind to the ND, and the tripeptide has to
approach and be recognized by the CD and positioned at the
active site. PaMpl-specific residues in helix H16 may affect how
the CD interacts with peptide substrate. Loop 161–171 that is near
the domain boundary of the ND and MD is not found in EcMpl.
As the protein domains separate to bind UDP-MurNAc, this
PaMpl-specific loop may control the extent to which the ND can
open and, in turn, may affect UDP-MurNAc binding. This
conformational rearrangement may explain the higher Km values
of PaMpl for UDP-MurNAc and tripeptide. The PaMpl-specific
segments 141–152, 161–171 and 262–285, which are not present
in EcMpl, might be responsible for its relative sensitivity to higher
temperature compared to EcMpl.
The Mur enzymes are established drug discovery targets as
disruption of peptidoglycan biosynthesis is a validated path to
bacterial cell death. The genes coding for the Mur ligases are
essential for bacterial survival, as demonstrated by knockout
experiments [3]. The recycling enzyme Mpl, although not essential
for growth, could also be considered an interesting target for drug
discovery. Indeed, deletion of the mpl gene and other genes involved
in peptidoglycan recycling increases antibiotic susceptibility of some
pathogenic strains. For instance, disruption of these non-essential
genes in Acinetobacter baylyi results in at least a 10-fold reduction in the
MIC of b-lactams [66]. The identification of the Mpl active site and
the structural determinants that correlate with its function may lead
to the design of better Mur inhibitors through structure-based drug
design. Such compounds could then shutdown both the de novo and
the recycling pathways for cell wall synthesis and act as novel
antimicrobial agents. Alternatively, as recently discussed [13], the
Table 2. Kinetic parameters of PaMpl a.
Substrate
Apparent
Km (mM)
Apparent
kcat (min
21)
Apparent
kcat/Km (min
21
/mM)
ATP 0.1160.05 260620 240061100
UDP-MurNAc 1.0060.13 260620 260639
L-Ala-c-D-Glu-meso-
A2pm
0.3660.08 260620 7206170
aThe concentrations of the fixed substrates were 5 mM for ATP, 0.4 mM for
UDP-MurNAc and 0.25 mM for L-Ala-c-D-Glu-meso-A2pm. The concentration
ranges for the varying substrates were 0.05 to 3 mM for ATP, 0.1 to 0.6 mM for
L-Ala-c-D-Glu-meso-A2pm, and 0.1 to 2 mM for UDP-MurNAc.
doi:10.1371/journal.pone.0017624.t002
Table 3. Substrate specificity of PaMpl.
Substrate k (min21)
L-Ala-c-D-Glu-meso-A2pm 260620
a
L-Ala-c-D-Glu-meso-A2pm-D-Ala 5.960.6
L-Ala-c-D-Glu-meso-A2pm-D-Ala-D-Ala 5.360.6
L-Ala 0.760.1
L-Ala-D-Glu 1.460.2
L-Ala-c-D-Glu-L-Lys 0.2560.05
L-Ala-c-D-Glu-L-Lys-D-Ala 0.1060.03
L-Ala-c-D-Glu-L-Lys-D-Ala-D-Ala NDb
The k (v/E) values were determined with 0.25 mM of meso-A2pm-containing
peptides, 4 mM of L-lysine-containing peptides, and 15 mM of L-Ala or L-Ala-D-
Glu.
aApparent kcat value.
bND, no detectable product formation under the experimental conditions used.
doi:10.1371/journal.pone.0017624.t003
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broad substrate specificity displayed by Mpl enzymes could
potentially be exploited as an Achilles’ heel for incorporation of
toxic peptides into the peptidoglycan network.
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